2014年美国临床肿瘤学会年会将于当地时间5月30日-6月3日在芝加哥召开，根据大会的会议日程，我国肿瘤专家徐兵河教授在6月2日上午有一项研究在“General Poster Session”中展出，下面和大家提前分享这项精彩研究。医脉通小编们今年也将继续奔赴ASCO年会现场，及时将各项最新研究进展整理、发布，欢迎大家保持关注！

三阴性乳腺癌（TNBC）可能对铂更敏感。本研究旨在比较铂类为基础的新辅助化疗与非铂方案治疗局部晚期三阴性乳腺癌患者的不同的病理学完全缓解（pCR）。

研究方法

符合条件的局部晚期三阴性乳腺癌女性接受紫杉醇（或多西他赛）-卡铂（TC）或紫杉醇（或多西他赛）-表柔比星（TE）q3W治疗4-6个疗程以上。主要终点指标是病理学完全缓解（pCR）率，定义为手术时乳腺和腋窝没有浸润性癌。次要终点指标为临床缓解率和无复发生存期（RFS）。

研究结果

2009年1月至2012年12月共有92例患者入选研究，其中，TC组43例，TE组49例。TC组pCR率较TE组高 （37.2％：16.1％，P = 0.032）。TC组和TE组临床缓解率相似（83.7％：87.8％，P=0.500）。两组间的3-4级中性粒细胞减少（TC：39.5％比TE：46.9％，P=0.399）和发热性中性粒细胞减少发生率无显著差异。周围神经病变常见，但不严重。TE组G3脱发比TC组更频繁。因随访时间所限，还没有进行RFS评估。

结论

这项研究表明，通过pCR检测发现，治疗局部晚期三阴性乳腺癌时，铂类为基础的新辅助化疗优于非铂类方案。但还有必要进行进一步的大规模前瞻性随机试验。

医脉通整理报道，转载请注明出处。

会议专题》》》2014年ASCO年会专题报道

阅读英文摘要

Differential response of neoadjuvant chemotherapy with taxane-carboplatin versus taxane-epirubicin in patients with locally advanced triple-negative breast cancer.（Abstract No:1105）

Authors: Jiayu Wang, Binghe Xu, Qing Li, Pin Zhang, et al.

Session Type: General Poster Session

Background: Triple-negative breast cancer (TNBC) may be more sensitive to platinum. The aim of this study was to compare the different pathologic complete response (pCR) in patients with locally advanced TNBC treated with platinum-based neoadjuvant chemotherapy with nonplatinum regimen. 

Methods: Eligible locally advanced TNBC women received either paclitaxel (or docetaxel)- carboplatin (TC) or paclitaxel (or docetaxel)- epirubicin (TE) q3w for up to 4-6 cycles. The primary end point was the rate of pathological complete response (pCR), defined as the absence of invasive cancer in the breast and axilla at the time of surgery. The second end point was the clinical response rate and recurrence free survival (RFS). 

Results: In total, 92 patients were enrolled between January 2009 and December 2012. Of these, 43 patients were assigned to TC group, and 49 to TE group. The pCR rate was higher in TC group than in TE group (37.2% versus 16.1%, p=0.032). The clinical response rates were similar in TC and TE group (83.7% versus 87.8%, p=0.500). The incidence of grade 3–4 neutropenia (TC: 39.5% versus TE: 46.9%, p=0.399) and febrile neutropenia, were not significantly different between two groups. Peripheral neuropathy was frequent but never severe. G3 alopecia was more frequent in TE group than in TC group. RFS has not been evaluated yet because of limited follow-up time. 

Conclusions: This study suggested that platinum-based chemotherapy was superior to nonplatinum regimen in the neoadjuvant treatment of locally advanced TNBC, as measured by pCR. Further large-scale prospective randomized trials are warranted.

(本网站所有内容，凡注明来源为“医脉通”，版权均归医脉通所有，未经授权，任何媒体、网站或个人不得转载，否则将追究法律责任，授权转载时须注明“来源：医脉通”。本网注明来源为其他媒体的内容为转载，转载仅作观点分享，版权归原作者所有，如有侵犯版权，请及时联系我们。)